Intravenous ferric carboxymaltose is associated with lowering of plasma phosphate levels in patients with gastric bypass surgery: a retrospective case series

Bibliographic Details
Title: Intravenous ferric carboxymaltose is associated with lowering of plasma phosphate levels in patients with gastric bypass surgery: a retrospective case series
Authors: Cindy Pereira Portela, Lucie Favre, Isabella Locatelli, Olivier Bonny
Source: Swiss Medical Weekly, Vol 154, Iss 7 (2024)
Publisher Information: SMW supporting association (Trägerverein Swiss Medical Weekly SMW), 2024.
Publication Year: 2024
Collection: LCC:Medicine
Subject Terms: Medicine
More Details: AIMS: Bariatric surgery induces several micronutrient deficiencies that require supplementation. For iron, parenteral infusions are usually preferred over oral supplementation. Ferric carboxymaltose infusion has been associated with hypophosphataemia, mostly transient and asymptomatic. However, in some cases, ferric carboxymaltose-induced hypophosphataemia may persist for weeks to months and may induce muscle weakness, osteomalacia and bone fractures. The aim of this study was to identify possible predictors of a clinically relevant decrease in serum phosphate after ferric carboxymaltose infusion in patients with previous Roux-en-Y gastric bypass. METHODS: Patients with previous Roux-en-Y gastric bypass who received ferric carboxymaltose infusions between January 2018 and September 2019 and had recorded phosphataemia before and after ferric carboxymaltose infusion at the Lausanne University Hospital, Lausanne, Switzerland, were studied retrospectively. A multiple linear regression model was built with delta phosphataemia as the outcome to investigate the factors related to magnitude of serum phosphate lowering. RESULTS: Seventy-seven patients (70 females and 7 males) with previous Roux-en-Y gastric bypass were studied. Mean age (SD) was 43.2 (10.7) years and median BMI was 30.9 kg/m2 (IQR 27.9–36.4). Sixty-eight patients (88.3%) received an infusion of 500 mg ferric carboxymaltose and 9 patients (11.7%) received 250 mg ferric carboxymaltose. Forty-nine patients (63.6%) developed hypophosphataemia (
Document Type: article
File Description: electronic resource
Language: English
ISSN: 1424-3997
Relation: https://smw.ch/index.php/smw/article/view/3771; https://doaj.org/toc/1424-3997
DOI: 10.57187/s.3771
Access URL: https://doaj.org/article/68dca7bfe74d47da8e635bc5bdf69a3b
Accession Number: edsdoj.68dca7bfe74d47da8e635bc5bdf69a3b
Database: Directory of Open Access Journals
More Details
ISSN:14243997
DOI:10.57187/s.3771
Published in:Swiss Medical Weekly
Language:English